New AI technology aims to enhance drug discovery and design efficiency.
- Persistent Systems introduces a new AI-driven platform.
- The technology aims to speed up the drug discovery process.
- Partnership with NVIDIA enhances the platform's capabilities.
Persistent Systems has launched a new AI-powered drug discovery solution that leverages generative molecules and virtual screening techniques. This innovative platform aims to optimize the process of drug design, making it more efficient and effective. By utilizing advanced technologies from NVIDIA, Persistent is set to enhance capabilities in pharmaceutical research and development.
The generative molecules and virtual screening approach offers researchers tools to explore vast chemical spaces rapidly. This means they can identify potential drug candidates more quickly than traditional methods would allow. The incorporation of NVIDIA technology enhances computational power, making it possible to analyze and predict molecular properties with increased accuracy.
Persistent's new solution stands to significantly impact sectors involved in drug research and development. With a focus on delivering advanced capabilities in identifying effective drug candidates, this launch aims to address challenges in the pharmaceutical industry and accelerate the timeline of bringing new therapies to market.
